SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (17568)3/18/1998 9:11:00 AM
From: Andrew H  Respond to of 32384
 
If Taxol is already a blockbuster and Targretin is more effective than Taxol, certainly Targetin has blockbuster potential.



To: Henry Niman who wrote (17568)3/18/1998 9:56:00 AM
From: PeterR1700  Read Replies (2) | Respond to of 32384
 
Henry - we've communicated in the past and I've appreciated your thoughts. To date, I haven't bought LGND primarily because I don't understand the business. (Not a chemist by any definition.) That said, todays announcement and activity suggest building strength. When do you "think" LGND will be profitable - and given my predeliction for long term plays - you like?

Peter
P.S. How large is the float?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News